ctDNA tumor fraction (TF) to predict response to nivolumab in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): An analysis of the multicentric phase 2 TOPNIVO trial.
Year: 2025
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Filippo Gustavo Dall'Olio, Wael Zrafi, Adsaya Rathakrishnan, Maeva Moreau, Rebecca Ibrahim, Matthieu Texier, Adrien Laville, Damien Vasseur, Patrick Saulnier, Amaury Daste, Karim Benihoud, Pierre Busson, Ivan Bieche, Clemence Toullec, Mariana Iacob, Roger Sun, Anne Auperin, Laure Monard, Ludovic Lacroix, Caroline Even
Institutions: Institut Gustave Roussy, Fondation Gustave Roussy, Inserm, Université de Bordeaux, Centre Hospitalier Universitaire de Bordeaux, Hôpital Saint-André, Centre National de la Recherche Scientifique, Université Paris-Saclay, Aspects métaboliques et systémiques de l'oncogénèse pour de nouvelles approches thérapeutiques, Institut Curie, Institut Sainte Catherine, UniCancer Group
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4410804936